Connect Biopharma Holdings Ltd (CNTB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Connect Biopharma reported revenue of $64,000, down 99.8% from $26.0M the year before. Net income was -$55.5M (a -86687.5% net margin), or -$1.00 per diluted share. Operating margin was -90740.6%. Operating activities generated -$51.2M of cash, leaving -$51.6M of free cash flow. At fiscal year end, Connect Biopharma held $56.1M in total assets against $14.1M in total liabilities, including $38.3M of cash and equivalents.
Open the full interactive Connect Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Connect Biopharma Key Stats
| Share Price | $0.92 |
|---|---|
| Market Cap | $57.8M |
| Revenue YoY Growth | -99.8% |
| 52-Week Range | $0.87 – $3.69 |
| Shares Outstanding | 62.9 million (basic, 2026 Q2) |
Connect Biopharma Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $26.0M | $64,000 |
| Operating Income | -$22.5M | -$58.1M |
| Pre-Tax Income | -$15.4M | -$55.3M |
| Income Tax | $223,000 | $197,000 |
| Net Income | -$15.6M | -$55.5M |
| Diluted EPS | -$0.28 | -$1.00 |
Connect Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $16,000 | $0 | $169,000 | $2.8M |
| Net Income | -$17.2M | -$15.1M | -$19.4M | -$17.3M |
| Diluted EPS | -$0.31 | -$0.27 | -$0.34 | -$0.27 |
Connect Biopharma Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $78.2M | $38.3M |
| Current Assets | $97.0M | $50.9M |
| Total Assets | $101.3M | $56.1M |
| Current Liabilities | $8.5M | $13.6M |
| Total Liabilities | $9.1M | $14.1M |
| Shareholders' Equity | $92.2M | $42.0M |
Connect Biopharma Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$23.6M | -$51.2M |
| Cash From Investing | -$3.5M | $9.8M |
| Cash From Financing | $227,000 | $1.1M |
| Free Cash Flow | -$24.4M | -$51.6M |
Figures from Connect Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Connect Biopharma financials page for every line item.
Connect Biopharma Company Profile
| Ticker | CNTB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001835268 |
Frequently Asked Questions
What was Connect Biopharma's revenue in fiscal 2025?
Connect Biopharma (CNTB) reported revenue of $64,000 for fiscal 2025.
What was Connect Biopharma's net income in fiscal 2025?
Connect Biopharma reported net income of -$55.5M for fiscal 2025.
What was Connect Biopharma's earnings per share (EPS) in fiscal 2025?
Connect Biopharma's diluted EPS was -$1.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Connect Biopharma generate in fiscal 2025?
Connect Biopharma generated -$51.6M of free cash flow in fiscal 2025.
What was Connect Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Connect Biopharma reported revenue of $2.8M.
How many shares of Connect Biopharma are outstanding?
Connect Biopharma reported a weighted average of 62.9 million basic shares outstanding in 2026 Q2.
What is Connect Biopharma's market cap?
Based on its latest closing price, Connect Biopharma (CNTB) has a market capitalization of about $57.8M.
When does Connect Biopharma's fiscal year end?
Connect Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Connect Biopharma headquartered?
Connect Biopharma lists its business address in San Diego, California in its SEC filings.